Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in COVID-19
NCT04615871Phase 2Unknown
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of semaglutide in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Composite of death from any cause or mechanical ventilation at 28 days. Status: unknown.
02
Drugs
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04615871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615871.